Treatment of gestational diabetes mellitus with myo-inositol: analyzing the cutting edge starting from a peculiar case.
CONCLUSIONS: On the one hand, we could confirm the safety profile of the molecule also at this high dosage, free from any side effects; on the other hand, our experience highlighted the faster glucose-lowering effect due to a higher dose of Myo-Ins. This outcome may open a new scenario in the treatment of GDM.
PMID: 28724184 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Diabetes | Diabetes Mellitus | Diets | Drugs & Pharmacology | Endocrinology | Nutrition | Obesity | Pregnancy